The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors

V. E. McGilligan, roisin Mcallister, Melody Chemaly, AJ Bjourson, Aaron Peace

Research output: Contribution to journalLiterature review

104 Downloads (Pure)

Abstract

Coronary Artery Disease (CAD) represents a major health burden worldwide. It is driven by chronic inflammation of the arterial vasculature supplying the heart, in response to pro-inflammatory assaults such as high LDL cholesterol. The resultant atherosclerosis can cause occlusive disease and acute cardiovascular events. The pro-inflammatory cytokine, IL-1β is a central component of this inflammatory response and signalling is activated and amplified by the NLRP3 inflammasome. Rational therapeutic targeting of these mediators could modify atherosclerotic disease progression; myocardial remodelling and CAD patient outcomes. Here we discuss promising current and pipeline inhibitors of the NLRP3 inflammasome family.
Original languageEnglish
Pages (from-to)1
Number of pages7
JournalOnline Journal of Cardiovascular Research
Volume2
Issue number3
Early online date13 Nov 2019
Publication statusPublished - 13 Nov 2019

Fingerprint Dive into the research topics of 'The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors'. Together they form a unique fingerprint.

  • Cite this